10-K: Mirum Pharma Reports Strong 2025 Revenue Growth, Advances Pipeline

Mirum Pharmaceuticals, Inc. reported significant revenue growth in 2025, driven by its approved rare disease medicines, while actively expanding its clinical pipeline and navigating ongoing patent litigation.

Summary

• Mirum Pharmaceuticals, Inc. is a biopharmaceutical company focused on rare diseases, with three approved medicines: LIVMARLI (maralixibat), CHOLBAM (cholic acid), and CTEXLI (chenodiol).
• Net product sales increased to $521.3 million in 2025 from $336.4 million in 2024, a 55% increase.
• The company reported a net loss of $23.4 million in 2025, a significant improvement from $87.9 million in 2024.
• LIVMARLI is approved for cholestatic pruritus in Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC) in multiple regions, with a market opportunity estimated at over $500.0 million for pediatric ALGS patients in the U.S. and Europe.
• CTEXLI received FDA approval in February 2025 for the treatment of adults with cerebrotendinous xanthomatosis (CTX), a rare bile acid synthesis disorder affecting an estimated 1,000-2,000 patients in the U.S.
• CHOLBAM is approved for bile acid synthesis disorders and peroxisomal disorders, with an estimated 200-300 prevalent patients in the U.S.
• The pipeline includes volixibat for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug for chronic hepatitis D virus (HDV) infection (acquired in January 2026), and MRM-3379 for fragile X syndrome (FXS).
• The Bluejay Therapeutics, Inc. acquisition in January 2026 added brelovitug, a late-stage monoclonal antibody for chronic HDV, with an upfront payment of $224.2 million cash and 4,673,597 shares of common stock.
• The company is engaged in patent litigation against generic manufacturers (Sandoz, Hetero, Biophore, Zydus) regarding LIVMARLI, with a 30-month stay on final regulatory approval through March 29, 2029.
• As of December 31, 2025, cash, cash equivalents, and investments totaled $391.4 million, up from $292.8 million in 2024.
• The company's accumulated deficit as of December 31, 2025, was $667.5 million.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive. While the company demonstrates strong revenue growth and significant pipeline advancements with multiple breakthrough designations and recent acquisitions, the continued net losses, reliance on third parties, and ongoing patent litigation introduce notable risks. The strategic expansion and promising clinical data are strong indicators, but the path to sustained profitability remains challenging.

Positives

• Product sales, net, increased significantly by $184.9 million (55%) to $521.3 million in 2025 from $336.4 million in 2024, driven by LIVMARLI and Bile Acid Medicines.
• Net loss substantially decreased to $23.4 million in 2025 from $87.9 million in 2024, indicating improved financial performance.
• CTEXLI received FDA approval in February 2025 for adults with CTX, expanding the commercialized product portfolio.
• LIVMARLI received FDA approval for cholestatic pruritus in PFIC patients and EMA approval for PFIC treatment, further broadening its market.
• Volixibat received FDA Breakthrough Therapy and Orphan Drug designations for cholestatic pruritus in PBC patients, and completed a successful interim analysis for PSC, accelerating its development pathway.
• Brelovitug (acquired in January 2026) has FDA Breakthrough Therapy, EMA PRIME, and European Commission orphan medicinal product designations, highlighting its potential.
• Cash, cash equivalents, and investments increased to $391.4 million as of December 31, 2025, from $292.8 million in 2024, strengthening liquidity.
• The Bluejay Acquisition adds a promising late-stage product candidate, brelovitug, for chronic HDV infection, diversifying the pipeline.

Negatives

• The company continues to incur substantial net losses, with an accumulated deficit of $667.5 million as of December 31, 2025, and anticipates continued losses for the foreseeable future.
• Reliance on third parties for manufacturing and distribution, including sole-source suppliers, poses risks of supply disruption, quality issues, and increased costs.
• Certain approved medicines, including CTEXLI and CHOLBAM, are or may be subject to immediate competition from compounded and generic entrants due to limited or no remaining patent or non-patent exclusivity.
• Ongoing LIVMARLI patent litigation against generic manufacturers could be costly, time-consuming, and, if unsuccessful, lead to generic competition and reduced revenue.
• The company is highly dependent on intellectual property licensed from third parties, and termination of any of these licenses could result in the loss of significant rights.
• The conditional conversion feature of the convertible notes may adversely affect financial condition and operating results, and conversion could dilute existing stockholders and create downward pressure on stock price.
• Changes in U.S. and foreign healthcare laws and regulations, such as the Inflation Reduction Act and proposed EU Pharma Package, could increase costs, reduce reimbursement, and limit market exclusivity.

Risks

• Inability to adequately grow, maintain, and scale marketing and sales capabilities or secure third-party agreements for commercialization.
• Failure of approved medicines or product candidates to achieve market acceptance among physicians, patients, and the medical community.
• Undesirable side effects or other properties of approved medicines or product candidates limiting commercial profile, leading to product liability claims, or delaying/preventing regulatory approval.
• Failure to comply with reporting and payment obligations under government pricing programs (e.g., Medicaid Drug Rebate Program) leading to fines, sanctions, or additional reimbursement requirements.
• Delays and difficulties enrolling patients in clinical trials, adversely affecting clinical development activities and timelines.
• Clinical trials failing to adequately demonstrate safety and efficacy of product candidates, preventing or delaying regulatory approval and commercialization.
• Lengthy and expensive clinical drug development process with uncertain outcomes, where earlier study results may not predict future trial results.
• Increased costs, delayed revenue generation, or adverse commercial prospects due to delays, termination, or suspension of clinical trials.
• Extensive and costly regulation and compliance for product candidates, potentially causing unanticipated delays or preventing regulatory approvals.
• Significant competition from other biotechnology and pharmaceutical companies, including those with greater resources or competing products/therapies.
• Failure to realize anticipated benefits from commercial and product candidate acquisitions (e.g., Bluejay Acquisition) or delays in integration.
• Dependence on intellectual property licensed from third parties, with termination of licenses leading to loss of significant rights.
• Need for substantial additional financing to continue commercialization, develop product candidates, or acquire new assets, with risk of delays or elimination of programs if financing is unavailable.
• Limitations on the ability to utilize net operating loss carryforwards and certain other tax attributes due to ownership changes or changes in tax laws.
• Indebtedness and liabilities limiting cash flow for operations and exposing the company to financial risks.
• Inability to protect intellectual property rights globally, including challenges to patents, trade secrets, and trademarks.
• Disruptions at regulatory authorities (FDA, EMA) due to layoffs, funding shortages, or global health concerns impacting review and approval times.
• Unfavorable geopolitical and macroeconomic developments (e.g., bank failures, tariffs, trade tensions, military conflicts, inflation) adversely affecting business and supply chain.
• Compromise of information technology systems or data (including sensitive patient and intellectual property information) leading to regulatory actions, litigation, fines, or business disruptions.
• Potential liability for damages if hazardous and biological materials are used improperly by third-party manufacturers.

Future Outlook

Mirum Pharmaceuticals expects to continue incurring net losses for the foreseeable future as it advances its product candidates through clinical development and commercialization. Key upcoming milestones include topline data from the VISTAS study (volixibat in PSC) in Q2 2026, completion of enrollment for the VANTAGE study (volixibat in PBC) in H2 2026, and topline data from the EXPAND study (Livmarli in other cholestatic settings) in Q4 2026. The company anticipates submitting an NDA for volixibat for PSC in H2 2026, with potential approval and launch in H1 2027. For brelovitug, topline results from the AZURE-1 and AZURE-4 registration-enabling trials are expected in H2 2026, potentially supporting a BLA submission in H1 2027 and launch in H2 2027. Topline data for MRM-3379 in FXS is expected in 2027, and for brelovitug AZURE-2 and AZURE-3 trials in H1 2028. The company projects total product sales of its approved medicines to continue increasing annually, though quarterly fluctuations are expected due to large periodic orders.

Management Comments

• Our goal is to strengthen our leadership position in rare and orphan diseases for which the unmet medical need is high.
• We intend to leverage our collective expertise to identify, acquire, in-license and advance additional product candidates for the treatment of rare and orphan diseases.
• Our financial objective is value creation through long-term cash-flow generating revenue growth.
• We aim to accomplish this by successfully commercializing current approved medicines and successfully developing and commercializing current and future clinical-stage product candidates.
• We believe our existing unrestricted cash, cash equivalents and investments will be sufficient to fund current operations through at least the next 12 months and beyond.

Industry Context

StockSavvy.ai notes that Mirum Pharmaceuticals operates in the highly competitive rare disease biopharmaceutical sector, characterized by significant R&D investment and intense competition. The company's focus on IBAT inhibitors for cholestatic liver diseases places it in direct competition with established players like Ipsen (Bylvay/Kayfanda) and GSK (linerixibat, with potential approval in 2026). The acquisition of brelovitug for chronic HDV positions Mirum against Gilead Sciences (bulevirtide, approved in EU and seeking FDA approval) and Vir Biotechnology (tobevibart). In the Fragile X Syndrome space, Mirum's MRM-3379 competes with Shionogi's zatomilast/BPN14770 and several other companies developing therapies. The broader industry trend of cost containment, exemplified by the U.S. Inflation Reduction Act and the proposed EU Pharma Package, poses significant challenges to drug pricing and market exclusivity, potentially impacting Mirum's future revenue and profitability. The recent U.S. Supreme Court decision in Loper Bright Enterprises v. Raimondo, reducing judicial deference to regulatory agencies, could also increase legal challenges to federal regulations affecting Mirum's operations.

Comparison to Industry Standards

• In cholestatic liver diseases, Mirum's LIVMARLI and volixibat compete with Ipsen's odevixibat (Bylvay/Kayfanda), approved for PFIC and ALGS, and GSK's linerixibat, which met its primary pruritus endpoint in Phase 3 for PBC with potential approvals in 2026.
• For Primary Biliary Cholangitis (PBC), existing therapies include Ursodeoxycholic acid (UDCA), obeticholic acid (Alfasigma S.p.s Ocaliva), seladelpar, and elafibranor (Ipsen's Iqirvo). Mirum's volixibat is in Phase 2b, competing with several agents in clinical development such as Alfasigma's bezafibrate, Zydus Therapeutics' saroglitazar magnesium, Calliditas Therapeutics' setanaxib, and others.
• For Primary Sclerosing Cholangitis (PSC), there are no FDA or European Commission approved therapeutics. Mirum's volixibat is in Phase 2b, competing with agents in clinical development from Dr. Falk Pharma (Norucholic acid), HighTide Therapeutics (HTD-1801), Alfasigma (Ocaliva), Ipsen (elafibranor and ritivixibat), NGM Biopharmaceuticals (NGM282), and others.
• In chronic Hepatitis D Virus (HDV) infection, Mirum's brelovitug (Phase 3) competes with Gilead Sciences' bulevirtide (approved in EU, seeking FDA approval) and Vir Biotechnology's tobevibart in combination with elebsiran, as well as other agents in clinical development from Shanghai HEP Pharmaceutical, Suzhou Ribo Life Science, Assembly Biosciences, Huahui Health, Replicor, and EIT Pharma.
• For Fragile X Syndrome (FXS), there are no FDA or European Commission approved therapeutics. Mirum's MRM-3379 (Phase 2) competes with Shionogi & Co., LTD.'s zatomilast/BPN14770 (another PDE4D inhibitor) and other therapies in clinical development from Harmony Biosciences, Allos Pharma, Healx Ltd., Spinogenix Inc., Connecta Therapeutics S.L., and Kaerus Therapeutics Inc.

Management Changes

Legal Proceedings

• On December 19, 2025, the company, along with Satiogen Pharmaceuticals, Inc. and Shire Human Genetic Therapies, Inc., filed four complaints in the U.S. District Court for the District of Delaware against Sandoz Inc., Annora Pharma Private Limited, Hetero Labs Limited, Hetero USA Inc., Zenara Pharma Private Limited, Biophore India Pharmaceuticals Private Limited, Zydus Lifesciences Global FZE, Zydus Lifesciences Limited, and Zydus Pharmaceuticals (USA) Inc. (collectively, Defendants).
• The complaints allege infringement of certain Orange Book listed patents covering LIVMARLI, following the Defendants' submission of Abbreviated New Drug Applications (ANDAs) for generic versions of LIVMARLI.
• The company is seeking an order that the effective date of any FDA approval of Defendants' ANDAs be no earlier than the expiration of the asserted patents.
• A 30-month stay of final regulatory approval is in place through March 29, 2029, preventing Defendants from marketing generic versions of LIVMARLI during this period.
• On February 20, 2026, Sandoz asserted counterclaims seeking declaratory judgments of non-infringement and invalidity with respect to certain LIVMARLI Patents.
• Trial in the LIVMARLI Patent Litigations has not yet been scheduled, and the final outcome or timing is unpredictable.

Related Party Transactions

• Entities affiliated with Frazier Life Sciences, which are associated with a member of the company's board of directors, were security holders of Bluejay Therapeutics, Inc. at the time of its acquisition in January 2026.

Stakeholder Impact

• **Shareholders:** Potential for dilution from future equity offerings and convertible note conversions. Stock price volatility is a risk due to clinical trial results, regulatory decisions, and competitive landscape. Ongoing patent litigation could impact long-term revenue and stock value.
• **Patients:** Continued development of therapies for rare diseases like ALGS, PFIC, CTX, PSC, PBC, HDV, and FXS offers hope for unmet medical needs. New approvals and expanded indications could improve treatment options.
• **Employees:** Company growth through acquisitions and pipeline expansion creates new opportunities but also integration challenges. Competition for skilled personnel is intense, potentially impacting compensation and retention.
• **Customers (Physicians, Payors, Specialty Pharmacies):** Availability of new approved medicines and expanded indications. Reimbursement challenges and cost-containment measures from payors could affect access and pricing. Reliance on single specialty pharmacies for distribution in the U.S. and Canada creates dependency.
• **Suppliers/Manufacturers:** Continued reliance on third-party contract manufacturers, including sole-source suppliers, for raw materials and finished products. Disruptions could impact supply chain and product availability.
• **Creditors:** The company's indebtedness from convertible notes creates fixed payment obligations, which could limit cash flow for other operations.

Next Steps

• Announce topline results from the VISTAS Phase 2b study (volixibat in PSC) in Q2 2026.
• Complete enrollment for the VANTAGE Phase 2b clinical trial (volixibat in PBC) in H2 2026.
• Announce topline results from the AZURE-1 and AZURE-4 registration-enabling clinical trials (brelovitug in HDV) in H2 2026.
• Announce topline results from the EXPAND study (Livmarli in additional cholestatic settings) in Q4 2026.
• Submit a New Drug Application (NDA) to the FDA for volixibat for the treatment of PSC in H2 2026.
• Submit a Biologics License Application (BLA) to the FDA for brelovitug in HDV in H1 2027.
• Potentially launch volixibat for PSC in H1 2027, if approved.
• Expect topline data from the VANTAGE Phase 2b clinical trial (volixibat in PBC) in H1 2027.
• Potentially launch brelovitug for HDV in H2 2027, if approved.
• Expect topline data from the BLOOM Phase 2 clinical study (MRM-3379 in FXS) in 2027.
• Expect topline results from the AZURE-2 and AZURE-3 registration-enabling clinical trials (brelovitug in HDV for EU registration) in H1 2028.
• Continue to acquire additional pipeline or commercial rare disease products or companies.

Key Dates

Recommendation

Mirum Pharmaceuticals demonstrates strong revenue growth from its commercialized rare disease products and has a robust pipeline with multiple promising candidates, including recent acquisitions and breakthrough designations. This indicates significant long-term potential. However, the company continues to operate at a net loss, faces intense competition, and is engaged in critical patent litigation that could impact its flagship product. The need for substantial future financing and the inherent risks of drug development and regulatory approval in rare diseases warrant a cautious approach. While the growth trajectory is positive, the existing financial and operational risks suggest a 'hold' recommendation for investors, advising to monitor pipeline progress, litigation outcomes, and the path to sustained profitability.

Keywords

Rare Diseases, Biopharmaceutical, LIVMARLI, Maralixibat, CHOLBAM, Cholic Acid, CTEXLI, Chenodiol, Alagille Syndrome, Progressive Familial Intrahepatic Cholestasis, Cerebrotendinous Xanthomatosis, Volixibat, Primary Sclerosing Cholangitis, Primary Biliary Cholangitis, Brelovitug, Hepatitis D Virus, MRM-3379, Fragile X Syndrome, IBAT Inhibitor, Monoclonal Antibody, PDE4D Inhibitor, Clinical Trials, Regulatory Approval, FDA Breakthrough Therapy, Orphan Drug Designation, Patent Litigation, Biologics License Application, New Drug Application, Commercialization, Biotech, Pharmaceuticals